Sign in
TerminatedPhase 1

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Key facts

Who runs it
Pfizer
Where
Anaheim, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
21 people enrolled
Started
13 Mar 2025
Ended
20 May 2025
Type of study
Interventional
Treatments tested
  • PF-07976016
  • PF-06882961
Record updated
7 August 2025
Why it stopped
The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age
  • BMI 25 to 40 kg/m2 and a total body weight > 50 kg (110 lb)
  • Willing and able to comply with all study procedures including staying a research unit for up to 95 days

Who cannot take part

  • Use of any prohibited prior or concomitant medication(s)
  • A positive urine drug test
  • History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
  • Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes
  • Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
  • Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day

Where in United States

  • Anaheim Clinical Trials, LLCAnaheim, United States

About the trial

What the trial wants to find out

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.

Read full original descriptionShow less

The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

The group in the trial

  • Period 1Treatment being tested

    Participants will receive doses of PF-07976016 with and without PF-06882961

    Treatment: PF-07976016 and PF-06882961

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
Record updated
7 August 2025